Cargando…

The path forward in prostate cancer therapeutics

The last decade has seen remarkable advances in the treatment of prostate cancer. Until 2010, only docetaxel had demonstrated the ability to improve the survival in metastatic castration-resistant prostate cancer (mCRPC).1 While effective, many men were reluctant to get treatment with docetaxel beca...

Descripción completa

Detalles Bibliográficos
Autores principales: Aragon-Ching, Jeanny B, Madan, Ravi A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952473/
https://www.ncbi.nlm.nih.gov/pubmed/29536949
http://dx.doi.org/10.4103/aja.aja_3_18